This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2008, p. 515-521, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01915-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005{triangledown}

M. A. Pfaller,1* D. J. Diekema,1,2 D. L. Gibbs,3 V. A. Newell,3 E. Nagy,4 S. Dobiasova,5 M. Rinaldi,6 R. Barton,7 A. Veselov,8 and the Global Antifungal Surveillance Group

Departments of Pathology,1 Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa,2 Giles Scientific, Inc., Santa Barbara, California,3 University of Szeged, Szeged, Hungary,4 Zdravotni ustav se sidlem v Ostrave, Ostrava, Czech Republic,5 University of Texas Health Sciences Center, San Antonio, Texas,6 Leeds General Infirmary, Leeds, United Kingdom,7 Institute of Antimicrobial Chemotherapy, Smolensk, Russia8

Received 27 September 2007/ Returned for modification 7 November 2007/ Accepted 4 December 2007

Candida krusei is well known as a fungal pathogen for patients with hematologic malignancies and for transplant recipients. Using the ARTEMIS Antifungal Surveillance Program database, we describe geographic and temporal trends in the isolation of C. krusei from clinical specimens and the in vitro susceptibilities of 3,448 isolates to voriconazole as determined by CLSI (formerly NCCLS) disk diffusion testing. In addition, we report the in vitro susceptibilities of bloodstream infection isolates of C. krusei to amphotericin B (304 isolates), flucytosine (254 isolates), anidulafungin (121 isolates), caspofungin (300 isolates), and micafungin (102 isolates) as determined by CLSI broth microdilution methods. Geographic differences in isolation were apparent; the highest frequency of isolation was seen for the Czech Republic (7.6%) and the lowest for Indonesia, South Korea, and Thailand (0 to 0.3%). Overall, 83% of isolates were susceptible to voriconazole, ranging from 74.8% in Latin America to 92.3% in North America. C. krusei was most commonly isolated from hematology-oncology services, where only 76.7% of isolates were susceptible to voriconazole. There was no evidence of increasing resistance of C. krusei to voriconazole from 2001 to 2005. Decreased susceptibilities to amphotericin B (MIC at which 90% of isolates were inhibited [MIC90], 4 µg/ml) and flucytosine (MIC90, 16 µg/ml) were noted, whereas 100% of isolates were inhibited by ≤2 µg/ml of anidulafungin (MIC90, 0.06 µg/ml), micafungin (MIC90, 0.12 µg/ml) or caspofungin (MIC90, 0.25 µg/ml). C. krusei is an uncommon but multidrug-resistant fungal pathogen. Among the systemically active antifungal agents, the echinocandins appear to be the most active against this important pathogen.

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu

{triangledown} Published ahead of print on 12 December 2007.

Journal of Clinical Microbiology, February 2008, p. 515-521, Vol. 46, No. 2
0095-1137/08/$08.00+0     doi:10.1128/JCM.01915-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Canton, E., Peman, J., Valentin, A., Espinel-Ingroff, A., Gobernado, M. (2009). In Vitro Activities of Echinocandins against Candida krusei Determined by Three Methods: MIC and Minimal Fungicidal Concentration Measurements and Time-Kill Studies. Antimicrob. Agents Chemother. 53: 3108-3111 [Abstract] [Full Text]  
  • Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C. (2009). Efflux-Mediated Antifungal Drug Resistance. Clin. Microbiol. Rev. 22: 291-321 [Abstract] [Full Text]  
  • Ostrosky-Zeichner, L., Paetznick, V. L., Rodriguez, J., Chen, E., Sheehan, D. J. (2009). Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-{beta}-D-Glucan Levels. Antimicrob. Agents Chemother. 53: 1639-1641 [Abstract] [Full Text]  
  • Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., Cannon, R. D. (2009). Abc1p Is a Multidrug Efflux Transporter That Tips the Balance in Favor of Innate Azole Resistance in Candida krusei. Antimicrob. Agents Chemother. 53: 354-369 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»